
India's proposed ban on paraquat dichloride could hit smaller agrochemical firms harder than large diversified players, according to a new analysis by Dr Donthi Narasimha Reddy. The draft Banning of Paraquat Dichloride…
India's proposed ban on paraquat dichloride could hit smaller agrochemical firms harder than large diversified players, according to a new analysis by Dr Donthi Narasimha Reddy. The draft Banning of Paraquat Dichloride Order, 2026, published on July 13 by the Ministry of Agriculture, would prohibit import, manufacture and sale under the Insecticides Act. The Indian paraquat market is estimated at Rs 1,500 crore. UPL has the largest absolute exposure but limited overall impact due to diversification. Crystal Crop Protection, which markets the Gramoxone brand, faces significant proportional risk. Inventory risk exists if the final order lacks a transition period, as some firms may have built up stocks anticipating the ban.
The focus on public health in the paraquat debate often overlooks the commercial disruption for smaller players who lack diversified portfolios. Large companies like UPL can absorb the loss, but specialty firms and importers built around this herbicide may struggle. The real test is whether the final order includes a sell-through period for existing stocks, or if it leaves small businesses stranded with unsaleable inventory. That detail will determine if the ban is fair as well as effective.
Source: newindianexpress.com
This story was synthesised by AI from the source linked above.